Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade
- Status
- COMPLETED
- Phase
- PHASE1
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
- Status
- COMPLETED
- Phase
- PHASE1
VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction
- Status
- COMPLETED
- Phase
- PHASE2